EBS
NYSEEmergent BioSolutions Inc.
News · 26 weeks59-29%
2026-04-192026-10-11
Mix1990d
- Other7(37%)
- SEC Filings4(21%)
- Earnings3(16%)
- Insider3(16%)
- Analyst1(5%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form 8-K filed by Emergent BioSolutions Inc.8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
- PREmergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. LindahlAppointment of Frank Vargo, VP, Treasurer, to Interim CFO effective January 1, 2027 Emergent BioSolutions Inc. (NYSE:EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer, will retire from the Company effective December 31, 2026. Frank Vargo, vice president, treasurer, will assume the role of interim chief financial officer effective January 1, 2027. To support a seamless transition, Rich will serve as a senior executive advisor from January 1 through March 31, 2027. "On behalf of the Board of Directors and our colleagues, I want to thank Rich for his exceptional leadership, partnership and commitment to Emergent, and importantly, his dedicati
- PREmergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Monday, November 2, 2026, at 5:00 p.m. eastern time to discuss the financial results for the third quarter of 2026. Participants can access the conference call via webcast and also by visiting the Investors page of Emergent’s website. Participants can pre-register for the teleconference at the following link and will receive an email with a calendar reminder, dial-in number and a unique code that allows immediate access to the call. To join by telephone on November 2: North America Toll-Free: +1 833-461-5787 International Toll: +1 585-542-9983 International Dial-Ins: https://help.events.q4inc.com/eahc/international-
- INSIDERSEC Form 4 filed by Emergent BioSolutions Inc.4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDERSVP, Products Business Williams Paul Anthony sold $19,590 worth of shares (3,000 units at $6.53) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 156,098 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- PRMedia Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing FacilityCompany leaders, elected officials and community stakeholders will come together on September 16, 2026 to mark milestone in advanced biopharmaceutical manufacturing CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing restart and growth of its Canton, Massachusetts facility and the company’s investment in the future of advanced biopharmaceutical manufacturing in the Commonwealth. The event will highlight Emergent's commitment to strengthening domestic manufacturing capabilities, supporting public health preparedness and creating opportunities for
- SECEmergent BioSolutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
- PREmergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured NotesRepurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the "Senior Unsecured Notes"), following authorization granted by its Board of Directors. In total, Emergent deployed approximately $68 million of cash for the repurchases, resulting in an average repurchase price of 90.6% of face value. Following completion of the repurchases
- SECEmergent BioSolutions Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
- PREmergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significant global biological threat due to its potential use in a bioterrorism event and its implications for public health and national security. "This newly executed CYFENDUS® contract modification with th
- PREmergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal SprayStanding offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer is effective from October 1, 2026, through September 30, 2029, with an option to extend for an additional two years. Under the standing offer, authorized federal departments, agencies, Crown corporations, provinces, territories and other designated public sector organizatio
- PREmergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness DayReady to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning preparedness across Canada GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE:EBS) is reaffirming its commitment to expanding awareness of opioid overdose risks and increasing preparedness to help save lives. According to the World Health Organization, opioids are associated with nearly 80 percent of drug-related deaths worldwide, highlighting the continued need for education, preparednes
- ANALYSTAnalyst resumed coverage on Emergent BioSolutionsAnalyst resumed coverage of Emergent BioSolutions with a rating of Underweight
- SECSEC Form SCHEDULE 13G filed by Emergent BioSolutions Inc.SCHEDULE 13G - Emergent BioSolutions Inc. (0001367644) (Subject)
- INSIDERNew insider Duatschek Stephanie claimed ownership of 197,416 shares (SEC Form 3)3 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- SECEmergent BioSolutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
- PREmergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security EnvironmentGAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning. In a recent event by the G
- PREmergent BioSolutions Reports Second Quarter 2026 Financial ResultsSecond Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment chargeSecond Quarter 2026 Adjusted Net Income of $30.9 million improved 134% versus prior yearSecond Quarter 2026 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 1400 bps and 900 bps, respectively, versus prior yearSecond Quarter 2026 Adjusted EBITDA of $96.5 million and Adjusted EBITDA Margin of 41%, an improvement of 1,800 bps versus prior yearRestructuring business operations to align resourcing to current needs; expected to result in annu
- PREmergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. eastern time to discuss the financial results for the second quarter of 2026. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can
- INSIDERSVP, Products Business Williams Paul Anthony sold $25,200 worth of shares (3,000 units at $8.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 159,098 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- SECEmergent BioSolutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
- PREmergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. GovernmentGAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries as well as diluent replacement lots for smallpox preparedness and response needs. Deliveries are expected to begin this month. "This new contract modification for ACAM2000® underscores the U.S. government’s continued focus on biodefense preparedness and reflects Emergent’s longstanding role to collaborate an
- INSIDERSVP, Products Business Williams Paul Anthony covered exercise/tax liability with 694 shares, decreasing direct ownership by 0.43% to 162,098 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDEREVP, Chief Financial Officer Lindahl Richard S covered exercise/tax liability with 3,964 shares, decreasing direct ownership by 1% to 374,083 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDEREVP, Quality & Ethics, and CPL Glessner Coleen covered exercise/tax liability with 2,018 shares, decreasing direct ownership by 0.99% to 202,201 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
EBS FAQ
7 questionsWhat does Emergent BioSolutions Inc. do?
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine...Where does EBS stock trade?
Emergent BioSolutions Inc. (EBS) is listed on NYSE.What sector and industry is EBS in?
Emergent BioSolutions Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Emergent BioSolutions Inc. go public?
Emergent BioSolutions Inc. (EBS) completed its IPO in 2006.What are analysts saying about EBS?
Emergent BioSolutions Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Underweight on 2026-08-21. Recent price targets range from $500.00 to $2200.00.What companies are similar to EBS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EBS side-by-side with any of them on Quantisnow.How can I track EBS on Quantisnow?
Quantisnow aggregates Emergent BioSolutions Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EBS to receive live email and push alerts on every new disclosure.